Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07365319 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
A Phase 2 study, sponsored by Eikon Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 750
- Enrollment target
NCT07365319 is a Phase 2 study that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 750 participants.
The verdict
NCT07365319, a Phase 2 study, is actively recruiting participants, sponsored by Eikon Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 750 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Interventions
- DRUG Placebo
- DRUG Pembrolizumab (KEYTRUDA®)
- DRUG EIK1001
- DRUG Paclitaxel + Carboplatin
- DRUG Nab-paclitaxel + Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2040-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07365319
The ClinicalTrials.gov registry entry for NCT07365319 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eikon Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT07365319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07365319 about?
NCT07365319 is a clinical study titled "A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.". This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
What is the current status of trial NCT07365319?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 750 participants. The study started on 2026-05-18. Estimated completion is 2040-12-31.
What interventions are being tested in trial NCT07365319?
The interventions under investigation include: Placebo (DRUG), Pembrolizumab (KEYTRUDA®) (DRUG), EIK1001 (DRUG), Paclitaxel + Carboplatin (DRUG), Nab-paclitaxel + Carboplatin (DRUG).
Who is sponsoring clinical trial NCT07365319?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.